The global glutamate receptor ionotropic NMDA 2B market is expected to grow at a CAGR of XX% during the forecast period. The growth of this market can be attributed to the increasing prevalence of neurological disorders such as autism, acute ischemic stroke, and Alzheimer's disease. The increase in the number of patients suffering from these disorders has led to an increased demand for glutamate receptor ionotropic NMDA 2B drugs. In addition, the growing awareness about these disorders among people has also contributed to the growth of this market. The global glutamate receptor ionotropic NMDA 2B market is segmented on the basis of type (JN0808, Ne2000, N10679, N11948), application (acute ischemic stroke, autism), and region (North America, Latin America, Europe). North America accounted for a major share in terms of revenue generated from sales in 2017 owing to its large population base and high per capita income. However Asia Pacific is expected to witness significant growth during the forecast period owing to its rapidly expanding pharmaceutical industry and increasing healthcare expenditure by governments across countries such as China and India.
- The NMDA receptor ionotropic 2B is a type of glutamate receptor that is activated by the neurotransmitter glutamate.
- It is a member of the N-methyl-D-aspartate (NMDA) subtype of ionotropic glutamate receptors, which are ligand-gated cation channels that allow for fast and efficient transmission of electrical signals across the cell membrane.
- The NMDA receptor ionotropic 2B has been implicated in many neurological disorders such as Alzheimer's disease, Parkinson's disease, and schizophrenia.
- Glutamate Receptor Ionotropic NMDA 2B market growth factors include increasing prevalence rates for neurological disorders such as Alzheimer's disease, Parkinson's disease, and schizophrenia; increasing research on potential therapeutic applications for glutamatergic drugs; and increased funding from government agencies to develop new treatments for these diseases.
Industry Growth Insights published a new data on “Glutamate Receptor Ionotropic NMDA 2B Market”. The research report is titled “Glutamate Receptor Ionotropic NMDA 2B Market research by Types (JNJ-0808, Neu-2000, NP-10679, NP-11948, Radiprodil, Others), By Applications (Acute Ischemic Stroke, Autism, Brasin Ischemia, Burns, Others), By Players/Companies BioCrea GmbH, Bristol-Myers Squibb Company, Cerecor Inc., Johnson & Johnson, Luc Therapeutics, Inc., NeurOp, Inc, Novartis AG, UCB S.A.”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Glutamate Receptor Ionotropic NMDA 2B Market Research Report
By Type
JNJ-0808, Neu-2000, NP-10679, NP-11948, Radiprodil, Others
By Application
Acute Ischemic Stroke, Autism, Brasin Ischemia, Burns, Others
By Companies
BioCrea GmbH, Bristol-Myers Squibb Company, Cerecor Inc., Johnson & Johnson, Luc Therapeutics, Inc., NeurOp, Inc, Novartis AG, UCB S.A.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Glutamate Receptor Ionotropic NMDA 2B Market Report Segments:
The global Glutamate Receptor Ionotropic NMDA 2B market is segmented on the basis of:
Types
JNJ-0808, Neu-2000, NP-10679, NP-11948, Radiprodil, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Acute Ischemic Stroke, Autism, Brasin Ischemia, Burns, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BioCrea GmbH
- Bristol-Myers Squibb Company
- Cerecor Inc.
- Johnson & Johnson
- Luc Therapeutics, Inc.
- NeurOp, Inc
- Novartis AG
- UCB S.A.
Highlights of The Glutamate Receptor Ionotropic NMDA 2B Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- JNJ-0808
- Neu-2000
- NP-10679
- NP-11948
- Radiprodil
- Others
- By Application:
- Acute Ischemic Stroke
- Autism
- Brasin Ischemia
- Burns
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glutamate Receptor Ionotropic NMDA 2B Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glutamate receptor ionotropic NMDA 2B is a subtype of glutamate receptor that is responsible for the transmission of nerve signals.
Some of the major companies in the glutamate receptor ionotropic nmda 2b market are BioCrea GmbH, Bristol-Myers Squibb Company, Cerecor Inc., Johnson & Johnson, Luc Therapeutics, Inc., NeurOp, Inc, Novartis AG, UCB S.A..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Glutamate Receptor Ionotropic NMDA 2B Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Glutamate Receptor Ionotropic NMDA 2B Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Glutamate Receptor Ionotropic NMDA 2B Market - Supply Chain
4.5. Global Glutamate Receptor Ionotropic NMDA 2B Market Forecast
4.5.1. Glutamate Receptor Ionotropic NMDA 2B Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Glutamate Receptor Ionotropic NMDA 2B Market Size (000 Units) and Y-o-Y Growth
4.5.3. Glutamate Receptor Ionotropic NMDA 2B Market Absolute $ Opportunity
5. Global Glutamate Receptor Ionotropic NMDA 2B Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Type
5.3.1. JNJ-0808
5.3.2. Neu-2000
5.3.3. NP-10679
5.3.4. NP-11948
5.3.5. Radiprodil
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Glutamate Receptor Ionotropic NMDA 2B Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Application
6.3.1. Acute Ischemic Stroke
6.3.2. Autism
6.3.3. Brasin Ischemia
6.3.4. Burns
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Glutamate Receptor Ionotropic NMDA 2B Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Glutamate Receptor Ionotropic NMDA 2B Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Glutamate Receptor Ionotropic NMDA 2B Demand Share Forecast, 2019-2029
9. North America Glutamate Receptor Ionotropic NMDA 2B Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Application
9.4.1. Acute Ischemic Stroke
9.4.2. Autism
9.4.3. Brasin Ischemia
9.4.4. Burns
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Type
9.7.1. JNJ-0808
9.7.2. Neu-2000
9.7.3. NP-10679
9.7.4. NP-11948
9.7.5. Radiprodil
9.7.6. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Glutamate Receptor Ionotropic NMDA 2B Demand Share Forecast, 2019-2029
10. Latin America Glutamate Receptor Ionotropic NMDA 2B Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Application
10.4.1. Acute Ischemic Stroke
10.4.2. Autism
10.4.3. Brasin Ischemia
10.4.4. Burns
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Type
10.7.1. JNJ-0808
10.7.2. Neu-2000
10.7.3. NP-10679
10.7.4. NP-11948
10.7.5. Radiprodil
10.7.6. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Glutamate Receptor Ionotropic NMDA 2B Demand Share Forecast, 2019-2029
11. Europe Glutamate Receptor Ionotropic NMDA 2B Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Application
11.4.1. Acute Ischemic Stroke
11.4.2. Autism
11.4.3. Brasin Ischemia
11.4.4. Burns
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast y Type
11.7.1. JNJ-0808
11.7.2. Neu-2000
11.7.3. NP-10679
11.7.4. NP-11948
11.7.5. Radiprodil
11.7.6. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Glutamate Receptor Ionotropic NMDA 2B Demand Share, 2019-2029
12. Asia Pacific Glutamate Receptor Ionotropic NMDA 2B Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Application
12.4.1. Acute Ischemic Stroke
12.4.2. Autism
12.4.3. Brasin Ischemia
12.4.4. Burns
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Type
12.7.1. JNJ-0808
12.7.2. Neu-2000
12.7.3. NP-10679
12.7.4. NP-11948
12.7.5. Radiprodil
12.7.6. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Glutamate Receptor Ionotropic NMDA 2B Demand Share, 2019-2029
13. Middle East & Africa Glutamate Receptor Ionotropic NMDA 2B Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Application
13.4.1. Acute Ischemic Stroke
13.4.2. Autism
13.4.3. Brasin Ischemia
13.4.4. Burns
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Glutamate Receptor Ionotropic NMDA 2B Market Size and Volume Forecast by Type
13.7.1. JNJ-0808
13.7.2. Neu-2000
13.7.3. NP-10679
13.7.4. NP-11948
13.7.5. Radiprodil
13.7.6. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Glutamate Receptor Ionotropic NMDA 2B Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Glutamate Receptor Ionotropic NMDA 2B Market: Market Share Analysis
14.2. Glutamate Receptor Ionotropic NMDA 2B Distributors and Customers
14.3. Glutamate Receptor Ionotropic NMDA 2B Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. BioCrea GmbH
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bristol-Myers Squibb Company
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Cerecor Inc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Luc Therapeutics, Inc.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. NeurOp, Inc
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Novartis AG
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. UCB S.A.
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook